J Korean Diabetes.  2023 Mar;24(1):5-11. 10.4093/jkd.2023.24.1.5.

Summary: Management of Hyperglycemia in Type 2 Diabetes according to the 2022 ADA-EASD Consensus Report and 2023 ADA Standards of Care in Diabetes

• Seo MH

• KMID: 2540914
• DOI: http://doi.org/10.4093/jkd.2023.24.1.5

Abstract

In October 2022, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) updated the previous consensus report for management of hyperglycemia in type 2 diabetes (T2DM). In January 2023, ADA Standards of Care in Diabetes with pharmacologic approaches to achieve a glycemic target were published to align with the consensus report by ADA and EASD. This recent consensus report and ADA Standards of Care in Diabetes emphasized weight management as an important aspect of the holistic approach to management of T2DM. In addition, it included numerous results of cardiorenal trials involving glucagon-like peptide 1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT2) inhibitor in type 2 diabetes. This information was added to address broader recommendations for cardiorenal risk reduction, in particular for organ (heart and kidney)-specific protection. This review summarizes the 2022 ADA-EASD consensus report and 2023 ADA standards of care for diabetes regarding management of hyperglycemia in T2DM.

Keyword

Diabetes mellitus, type 2; Drug therapy; Guideline; Heart; Kidney

Reference

1.Davies MJ., Aroda VR., Collins BS., Gabbay RA., Green J., Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022. 45:2753–86.

2.ElSayed NA., Aleppo G., Aroda VR., Bannuru RR., Brown FM., Bruemmer D., American Diabetes Association, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023. 46(Suppl 1):S140–57.

3.Davies MJ., D'Alessio DA., Fradkin J., Kernan WN., Mathieu C., Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018. 41:2669–701.

4.Buse JB., Wexler DJ., Tsapas A., Rossing P., Mingrone G., Mathieu C, et al. 2019 update to: management of hyper-glycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020. 63:221–8. Erratum in: Diabetologia. 2020. 63:1667

5.ElSayed NA., Aleppo G., Aroda VR., Bannuru RR., Brown FM., Bruemmer D., American Diabetes Association, et al. Summary of revisions: Standards of Care in Diabetes-2023. Diabetes Care. 2023. 46(Suppl 1):S5–9.

6.ElSayed NA., Aleppo G., Aroda VR., Bannuru RR., Brown FM., Bruemmer D., American Diabetes Association, et al. 11. Chronic kidney disease and risk management: Standards of Care in Diabetes-2023. Diabetes Care. 2023. 46(Suppl 1):S191–202.

7.ElSayed NA., Aleppo G., Aroda VR., Bannuru RR., Brown FM., Bruemmer D., American Diabetes Association, et al. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023. 46(Suppl 1):S128–39.

8.Lingvay I., Sumithran P., Cohen RV., le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022. 399:394–405. Erratum in: Lancet 2022;399):358.

9.ElSayed NA., Aleppo G., Aroda VR., Bannuru RR., Brown FM., Bruemmer D., American Diabetes Association, et al. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes-2023. Diabetes Care. 2023. 46(Suppl 1):S49–67.